<?xml version='1.0' encoding='utf-8'?>
<document id="31950545"><sentence text="Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany." /><sentence text="Various first-line recommended antiretroviral therapy (ART) regimens have different drug-drug interaction (DDI)/contraindication profiles" /><sentence text=" The aim of this study was to estimate the rate of potential DDIs/contraindications of real-world prescribed non-ART comedication with first-line recommended ART in people living with HIV (PLHIV) in Germany" /><sentence text="" /><sentence text="A retrospective, cross-sectional cohort design was used to collect non-ART comedication prescription data from a representative sample of a German health insurance claims database" /><sentence text=" PLHIV who were prescribed ART during 2016 were included in the analysis" /><sentence text=" Patients were stratified by sex, age, comorbidities, and time on ART" /><sentence text=" Prescribed comedications were used to estimate potential DDIs/contraindications for each recommended first-line ART per patient based on criteria from www" /><sentence text="hiv-druginteractions" /><sentence text="org" /><sentence text="" /><sentence text="Records from 2680 PLHIV were analyzed" /><sentence text=" Prescriptions for non-ART comedications were common (mean of seven per patient in the overall population, 10" /><sentence text="2 in PLHIV aged 50 years and older)" /><sentence text=" Antiretroviral regimens with the lowest proportion of patients with at least 1 potential DDI/contraindication were unboosted integrase inhibitor, non-tenofovir disoproxil fumarate-based regimens that included raltegravir + emtricitabine/tenofovir alafenamide fumarate (13%), dolutegravir + lamivudine (14%), dolutegravir/abacavir/lamivudine (14%), dolutegravir/emtricitabine/tenofovir alafenamide fumarate (15%), and bictegravir/emtricitabine/tenofovir alafenamide fumarate (19%)"><entity charOffset="151-180" id="DDI-PubMed.31950545.s15.e0" text="tenofovir disoproxil fumarate" /><entity charOffset="210-237" id="DDI-PubMed.31950545.s15.e1" text="raltegravir + emtricitabine" /><entity charOffset="238-268" id="DDI-PubMed.31950545.s15.e2" text="tenofovir alafenamide fumarate" /><entity charOffset="276-301" id="DDI-PubMed.31950545.s15.e3" text="dolutegravir + lamivudine" /><entity charOffset="309-321" id="DDI-PubMed.31950545.s15.e4" text="dolutegravir" /><entity charOffset="322-330" id="DDI-PubMed.31950545.s15.e5" text="abacavir" /><entity charOffset="331-341" id="DDI-PubMed.31950545.s15.e6" text="lamivudine" /><entity charOffset="349-361" id="DDI-PubMed.31950545.s15.e7" text="dolutegravir" /><entity charOffset="362-375" id="DDI-PubMed.31950545.s15.e8" text="emtricitabine" /><entity charOffset="376-406" id="DDI-PubMed.31950545.s15.e9" text="tenofovir alafenamide fumarate" /><entity charOffset="418-429" id="DDI-PubMed.31950545.s15.e10" text="bictegravir" /><entity charOffset="430-443" id="DDI-PubMed.31950545.s15.e11" text="emtricitabine" /><entity charOffset="444-474" id="DDI-PubMed.31950545.s15.e12" text="tenofovir alafenamide fumarate" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e0" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e1" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e2" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e3" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e4" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e5" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e6" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e7" e2="DDI-PubMed.31950545.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e7" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e7" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e7" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e7" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e7" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e8" e2="DDI-PubMed.31950545.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e8" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e8" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e8" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e8" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e9" e2="DDI-PubMed.31950545.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e9" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e9" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e9" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e10" e2="DDI-PubMed.31950545.s15.e10" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e10" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e10" e2="DDI-PubMed.31950545.s15.e12" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e11" e2="DDI-PubMed.31950545.s15.e11" /><pair ddi="false" e1="DDI-PubMed.31950545.s15.e11" e2="DDI-PubMed.31950545.s15.e12" /></sentence><sentence text=" Boosted regimens and efavirenz-based regimens presented the highest potential for DDIs/contraindications"><entity charOffset="22-31" id="DDI-PubMed.31950545.s16.e0" text="efavirenz" /></sentence><sentence text="" /><sentence text="Comedication with potential DDIs/contraindications with ART is frequently prescribed among PLHIV in Germany" /><sentence text=" Potential risks for DDIs/contraindications vary by ART, with the lowest potential seen in unboosted integrase strand transfer inhibitor-based regimens, including raltegravir + emtricitabine/tenofovir alafenamide fumarate, followed by three dolutegravir-based regimens"><entity charOffset="163-190" id="DDI-PubMed.31950545.s19.e0" text="raltegravir + emtricitabine" /><entity charOffset="191-221" id="DDI-PubMed.31950545.s19.e1" text="tenofovir alafenamide fumarate" /><entity charOffset="241-253" id="DDI-PubMed.31950545.s19.e2" text="dolutegravir" /><pair ddi="false" e1="DDI-PubMed.31950545.s19.e0" e2="DDI-PubMed.31950545.s19.e0" /><pair ddi="false" e1="DDI-PubMed.31950545.s19.e0" e2="DDI-PubMed.31950545.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31950545.s19.e0" e2="DDI-PubMed.31950545.s19.e2" /><pair ddi="false" e1="DDI-PubMed.31950545.s19.e1" e2="DDI-PubMed.31950545.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31950545.s19.e1" e2="DDI-PubMed.31950545.s19.e2" /></sentence><sentence text="" /></document>